加拿大医生使用肉毒杆菌毒素-A（BoNT-A）治疗瘫痪的调查：真实世界的洞察力。

IF 2.9 4区医学 Q2 CLINICAL NEUROLOGY

Canadian Journal of Neurological Sciences Pub Date : 2024-04-01 DOI:10.1017/cjn.2024.46

Galit Kleiner, Farooq Ismail, Omar Khan, Christopher Pilieci, Linda Truong, Chris Boulias

{"title":"加拿大医生使用肉毒杆菌毒素-A（BoNT-A）治疗瘫痪的调查：真实世界的洞察力。","authors":"Galit Kleiner, Farooq Ismail, Omar Khan, Christopher Pilieci, Linda Truong, Chris Boulias","doi":"10.1017/cjn.2024.46","DOIUrl":null,"url":null,"abstract":"Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights.\",\"authors\":\"Galit Kleiner, Farooq Ismail, Omar Khan, Christopher Pilieci, Linda Truong, Chris Boulias\",\"doi\":\"10.1017/cjn.2024.46\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.\",\"PeriodicalId\":56134,\"journal\":{\"name\":\"Canadian Journal of Neurological Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/cjn.2024.46\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/cjn.2024.46","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肌张力瘫痪是一种肌张力过高症，其特点是在认知障碍的情况下无法放松肌肉。肌张力障碍会导致疼痛、拒绝护理和护理负担。我们向 67 位加拿大理疗医师和神经科医师发送了调查问卷，了解他们使用 A 型肉毒毒素（BoNT-A）治疗肌张力障碍的经验。27名调查对象被纳入分析范围。在使用 BoNT-A 治疗肌张力障碍的调查对象中，13% 的人表示临床症状有明显改善；74% 的人表示临床症状有适度改善；13% 的人表示临床症状有轻微改善。90%的调查对象认为使用 BoNT-A 治疗精神分裂症有明显障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights.

Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Canadian Journal of Neurological Sciences 医学-临床神经学

CiteScore

4.30

自引率

3.30%

发文量

330

审稿时长

4-8 weeks

期刊介绍： Canadian Neurological Sciences Federation The Canadian Journal of Neurological Sciences is the official publication of the four member societies of the Canadian Neurological Sciences Federation -- Canadian Neurological Society (CNS), Canadian Association of Child Neurology (CACN), Canadian Neurosurgical Society (CNSS), Canadian Society of Clinical Neurophysiologists (CSCN). The Journal is a widely circulated internationally recognized medical journal that publishes peer-reviewed articles. The Journal is published in January, March, May, July, September, and November in an online only format. The first Canadian Journal of Neurological Sciences (the Journal) was published in 1974 in Winnipeg. In 1981, the Journal became the official publication of the member societies of the CNSF.